Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin.

ABSTRACT:

Background

Mavacamten use has potential for clinically significant ventricular systolic dysfunction, including with drug-drug interactions (DDI).

Case summary

A 66-year-old male with symptomatic obstructive hypertrophic cardiomyopathy was treated with mavacamten for 1.5 years. He received treatment for Helicobacter pylori infection with a combination therapy including clarithromycin. The patient developed cardiogenic shock (ejection fraction nadir of 21%) in the setting of new atrial fibrillation (AF) with rapid ventricular response and pulmonary infiltrates. A DDI between clarithromycin and mavacamten was felt to precipitate clinical decline. In this case, cardiogenic shock occurred in the setting of clarithromycin, AF, and possible infection. The CYP3A4 inhibitory effect o

SUBMITTER: Alabdaljabar MS 

PROVIDER: S-EPMC12540262 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature